Vince Anzalone
Vice President of Investor Relations
Replay available
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) Q3 2025 earnings conference call, held 2025-08-07. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Chris Anzalone
President and Chief Executive Officer
Dr. Bruce Gibbons
Interim Chief Medical Scientist
Andy Davis
Senior Vice President and Head of the Global Cardiometabolic Franchise
Dr. James Hamilton
Chief Medical Officer and Head of R&D
Dan Appel
Chief Financial Officer
Jason Gerberry
Analyst, Bank of America
Mary Kate
Analyst, Citi (covering for David Leibowitz)
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Arrowhead Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.599 Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. 00:00:04.599 -- 00:00:09.468 Throughout today's recorded presentation, all participants will be in a listen-only mode. 00:00:09.468 -- 00:00:13.075 After the presentation, there will be an opportunity to ask questions. 00:00:13.075 -- 00:00:18.204 I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations 00:00:18.204 -- 00:00:21.580 for Arrowhead. Please go ahead, Vince. 00:00:21.580 -- 00:00:22.343 Thank you. 00:00:22.343 -- 00:00:26.663 Good afternoon, everyone. Thank you for joining us today to discuss Arrowhead's results 00:00:26.663 -- 00:00:31.705 for its fiscal 2025 third quarter ended June 30, 2025. 00:00:31.705 -- 00:00:34.789 With us today for management are President and CEO, Dr. 00:00:34.789 -- 00:00:37.473 Chris Anzalone, who will provide an overview. 00:00:37.473 -- 00:00:41.980 Dr. Bruce Gibbon, Interim Chief Medical Scientist, who will provide an update on late 00:00:41.980 -- 00:00:47.688 clinical and regulatory. Andy Davis, Senior Vice President and Head of the Global Cardiometabolic 00:00:47.688 -- 00:00:51.894 Franchise, who will provide an update on commercialization activities. 00:00:51.894 -- 00:00:56.621 Dr. James Hamilton, Chief Medical Officer and Head of R&D, who will discuss our earlier 00:00:56.621 -- 00:01:01.688 stage development programs. and Dan Appel, Chief Financial Officer, who will give a review 00:01:01.688 -- 00:01:06.775 of the financials. Following management's prepared remarks, we will open the call to 00:01:06.775 -- 00:01:08.377 questions. 00:01:08.377 -- 00:01:12.422 Before we begin, I would like to remind you the comments made during today's call contain 00:01:12.422 -- 00:0...